1498 — PuraPharm Income Statement
0.000.00%
Last trade - 00:00- HK$192.01m
- HK$542.98m
- HK$382.09m
- 18
- 63
- 30
- 27
Annual income statement for PuraPharm, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 602 | 660 | 448 | 407 | 382 |
| Cost of Revenue | |||||
| Gross Profit | 370 | 423 | 263 | 219 | 205 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 535 | 750 | 543 | 482 | 387 |
| Operating Profit | 67 | -90.2 | -95 | -74.8 | -5.12 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 40.2 | -117 | -119 | -102 | -29.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 31.7 | -122 | -120 | -106 | -35.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 31.7 | -122 | -120 | -106 | -35.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 31.7 | -122 | -120 | -106 | -35.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.1 | -0.293 | -0.377 | -0.23 | -0.104 |